DelveInsight's "Prurigo Nodularis Market Insights, Epidemiology, and Market Forecast-2034" report provides a comprehensive analysis of Prurigo Nodularis, including historical and forecasted epidemiology, market trends, and drug developments in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Traumatic Brain Injury Market to Grow at a CAGR of 10.9% During 2020–2034, Driven by Therapeutic Innovation and Rising Healthcare Investments
Systemic lupus erythematosus therapeutics market in the 7MM is projected to grow steadily through 2036. DelveInsight’s report, “Systemic Lupus Erythematosus Treatment Market Insights, Epidemiology and Market Forecast – 2036,” analyzes disease burden, epidemiology trends, and market dynamics across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Bristol Myers Squibb has reached a milestone that the multiple myeloma treatment pipeline has been building toward for years. In August 2026, the FDA granted accelerated approval to Zenbexus (iberdomide), positioning it as the first-in-class CelMoD drug to reach the U.S. market. This approval is not just another entry on the growing list of FDA-approved multiple myeloma drugs it represents a structural shift in how new therapies for this blood cancer can be evaluated and brought to patients faster than ever before.
Bristol Myers Squibb has reached a milestone that the multiple myeloma treatment pipeline has been building toward for years. In August 2026, the FDA granted accelerated approval to Zenbexus (iberdomide), positioning it as the first-in-class CelMoD drug to reach the U.S. market. This approval is not just another entry on the growing list of FDA-approved multiple myeloma drugs it represents a structural shift in how new therapies for this blood cancer can be evaluated and brought to patients faster than ever before.
Graves' Orbitopathy Market Expected to Grow at a CAGR of 19.8% Between 2025 and 2034
Chronic Hepatitis B Virus Clinical Trials
The myasthenia gravis market is entering one of its most dynamic phases yet. According to DelveInsight's analysis, the market across the seven major markets (US, EU4, UK, and Japan) was valued at approximately USD 6 billion in 2025, with roughly 300,000 diagnosed prevalent cases reported across these regions. Growth is being driven by a wave of targeted biologics that have shifted treatment away from broad immunosuppression toward precision immunotherapy.
Gene therapy has moved from an experimental concept to a clinically validated treatment modality, offering the possibility of one-time, potentially curative interventions for diseases that were once considered untreatable. By directly correcting, replacing, or silencing faulty genes, gene therapy is redefining how the medical community approaches inherited disorders, oncology, neurological conditions, and rare diseases. As regulatory approvals accumulate and manufacturing capabilities mature, the Gene Therapy Market is entering a phase of rapid commercial expansion, attracting significant investment from biopharmaceutical companies, venture capital, and government research bodies alike.
From Pill Reminders to AI Health Coaches: Why Chronic Disease Management Apps Are Becoming Essential
According to DelveInsight’s latest analysis, the Pulmonary Arterial Hypertension (PAH) market is projected to witness substantial growth through 2034, driven by rising disease prevalence, improved awareness, and continued innovation across therapeutic classes. Major companies shaping the competitive landscape include Aerovate Therapeutics, Novartis, Keros Therapeutics, Insmed Incorporated, Chugai Pharmaceutical, Merck Sharp & Dohme, Janssen Pharmaceutical, Actelion, Gossamer Bio, United Therapeutics, Gilead Sciences, AstraZeneca, and others.
The intersection of neuroscience and medical technology has given rise to one of the most transformative therapeutic innovations of recent decades. The vagus nerve stimulator a small implantable or wearable device that delivers electrical impulses to the body's longest cranial nerve is redefining how physicians approach conditions that have long resisted conventional pharmacological treatment. From drug-resistant epilepsy to treatment-resistant depression, the scope of vagus nerve stimulation VNS continues to expand, attracting significant attention from clinicians, researchers, and the MedTech industry alike.
Degenerative Disc Disease (DDD) is a major contributor to persistent spinal pain, reduced mobility, and disability, particularly among aging populations. As the burden of chronic lower back pain continues to increase, healthcare professionals and researchers are looking beyond conventional symptom-management strategies toward therapies that may address the biological causes of disc degeneration.
For pharmaceutical executives, biotech leadership teams, and healthcare investors, clinical development and commercial strategy no longer operate on separate tracks from regulatory planning they move together, or they don't move efficiently at all. A misaligned regulatory pathway, an underprepared submission, or a missed health authority meeting can delay a launch by years and quietly erode enterprise value. This is why regulatory affairs consulting has become a distinct and increasingly strategic discipline, sitting at the intersection of clinical evidence generation, market access planning, and global regulatory intelligence.
Exploring the Impact of AI in Mental Health: How It Is Going to Revolutionize Diagnosis and Treatment for a Better Tomorrow?
Understanding FAAH Inhibitors and Their Role in Modern Therapeutics
The influx of companies, the launch of pipeline therapies, and the ongoing legalization of marijuana and cannabis are the major drivers reshaping the medical marijuana market today.
Rare autoimmune diseases rarely generate the headlines they deserve yet for patients and pharmaceutical companies alike, the stakes could not be higher. One such condition is diffuse cutaneous systemic sclerosis, a severe and progressive subtype of systemic sclerosis characterised by widespread skin thickening, vascular damage, and the threat of serious internal organ involvement. Understanding both the disease and the evolving landscape around it has become a strategic priority for researchers, clinicians, and investors navigating the rare disease space.
The global heart pump device market is entering a period of rapid transformation. Valued at roughly USD 3.14 billion in 2024, the market is projected to expand to nearly USD 9.75 billion by 2032, growing at a compound annual rate of over 15% through the forecast period. This growth is being driven by the rising global burden of cardiovascular disease, a persistent shortage of donor hearts for transplant, and continuous miniaturization and technological refinement of mechanical circulatory support devices. As the patient pool for advanced heart failure expands worldwide, the heart pump devices market is shifting from a niche surgical specialty into a mainstream pillar of cardiac care.
The pharmaceutical and healthcare landscape is evolving faster than ever, shaped by breakthrough therapies, shifting regulatory frameworks, evolving patient needs, and intensifying competition among global drugmakers. In such a dynamic environment, decision-makers across pharma, biotech, and medtech companies need more than instinct they need data-backed clarity. This is where dedicated Pharmaceutical market Research for latest healthcare and pharmaceutical research, pharmaceutical industry analysis through pharma and healthcare market research reports becomes indispensable, offering the strategic foundation that companies rely on to make confident, informed decisions.